Daily Stock Analysis, ATOS, Atossa Genetics Inc, priceseries

Atossa Genetics Inc. Daily Stock Analysis
Stock Information
Open
1.62
Close
1.53
High
1.63
Low
1.53
Previous Close
1.62
Daily Price Gain
-0.09
YTD High
1.95
YTD High Date
Feb 7, 2019
YTD Low
0.99
YTD Low Date
Jan 2, 2019
YTD Price Change
0.37
YTD Gain
31.90%
52 Week High
9.99
52 Week High Date
Mar 8, 2018
52 Week Low
0.80
52 Week Low Date
Dec 26, 2018
52 Week Price Change
-6.76
52 Week Gain
-81.54%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 29. 2017
6.60
Jun 30. 2017
7.14
1 Trading Days
8.18%
Link
LONG
Jan 25. 2018
3.90
Feb 6. 2018
6.93
8 Trading Days
77.76%
Link
LONG
Feb 8. 2018
7.30
Feb 9. 2018
7.79
1 Trading Days
6.68%
Link
LONG
Jan 4. 2019
1.19
Jan 14. 2019
1.31
6 Trading Days
10.13%
Link
Company Information
Stock Symbol
ATOS
Exchange
NasdaqCM
Company URL
http://www.atossagenetics.com
Company Phone
206.588.0256
CEO
Steven C. Quay
Headquarters
Washington
Business Address
107 SPRING STREET, SEATTLE, WA 98104
Sector
Equity
Industry Category
Drugs
Industry Group
Diagnostic Substances
CIK
0001488039
About

Atossa Genetics, Inc. is a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Description

Atossa Genetics Inc., a clinical-stage pharmaceutical company, focuses on developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions in the United States. The company is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Afimoxifene Topical Gel for the treatment and prevention of hyperplasia of the breast. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.